The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II trial of carboplatin combined with weekly paclitaxel (CP) and docetaxel alone (D) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): NJLCG 0801.
Shunichi Sugawara
Honoraria - Sanofi
Makoto Maemondo
Honoraria - Sanofi
Toshiyuki Harada
No relevant relationships to disclose
Akira Inoue
Honoraria - Sanofi
Nobumichi Matsubara
No relevant relationships to disclose
Kana Watanabe
No relevant relationships to disclose
Osamu Ishimoto
No relevant relationships to disclose
Tomohiro Sakakibara
No relevant relationships to disclose
Yuji Minegishi
No relevant relationships to disclose
Kazuhiro Usui
No relevant relationships to disclose
Masahiro Ando
No relevant relationships to disclose
Naoto Morikawa
No relevant relationships to disclose
Yoshiaki Mori
No relevant relationships to disclose
Akihiko Gemma
No relevant relationships to disclose
Toshihiro Nukiwa
No relevant relationships to disclose